To demonstrate this, we examined IC50 (half maximal inhibitory concentration) levels of LUAD cell lines to EGFR inhibitors with respect to the mutational status of EGFR and KRAS as obtained in GDSC (Genomics of Drug Sensitivity in Cancer) [31] (Fig. 5b). The gene discussed is KRAS; the disease is cancer.